Keele Research Repository

Article

Chapman, SR ORCID: https://orcid.org/0000-0002-0326-7742, Fitzapatrick, R and Aladul, M ORCID: https://orcid.org/0000-0002-7368-3469 (2019) Differences in UK healthcare professionals" knowledge,,attitude and practice towards infliximab and insulin glargine biosimilars. International Journal of Pharmacy Practice, 27 (2). pp. 214-217.

Aladul, M ORCID: https://orcid.org/0000-0002-7368-3469, Fitzpatrick, RW and Chapman, SR ORCID: https://orcid.org/0000-0002-0326-7742 (2019) The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis. Research in Social & Administrative Pharmacy, 15 (3). pp. 310-317.

Chapman, SR ORCID: https://orcid.org/0000-0002-0326-7742, Fitzpatrick, R and Aladul, M (2017) Has cost inhibited the uptake of more potent statins in England? Pharmacoepidemiology and Drug Safety, 26 (8). pp. 984-991.

Chapman, SR ORCID: https://orcid.org/0000-0002-0326-7742, Aladul, M ORCID: https://orcid.org/0000-0002-7368-3469 and Fitzpatrick, R (2017) Patient's Understanding and Attititudes Towards Infliximab and Etanercept Biosimilars. BioDrugs. pp. 1-8.

Chapman, SR ORCID: https://orcid.org/0000-0002-0326-7742, Fitzpatrick, R and Aladul, M (2017) Patients’ understanding and attitudes towards infliximab and etanercept biosimilars: result of a UK web-based survey. BioDrugs, 31. pp. 439-446.

Conference or Workshop Item

Aladul, M, Fitzpatrick, R and Chapman, SR ORCID: https://orcid.org/0000-0002-0326-7742 (2017) Aladul M, Fitzpatrick R, Chapman S. CP-024 Factors affecting uptake of biosimilars Eur J Hosp Pharm 2017;24:A10-A11. In: European Assocaiation of Hospital Pharmacists.